EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial

Yugo Yamashita iD, Takeshi Morimoto iD, Nao Muraoka, Takuya Oyakawa, Michihisa Umetsu iD, Daijirou Akamatsu iD, Yuji Nishimoto iD, Yukihito Sato iD, Takuma Takada iD, Kentaro Jujo iD, Yuichiro Minami, Yoshito Ogihara iD und 22 weitere

Circulation · 2023

DOI: 10.1161/circulationaha.123.066360 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation, 2023. Verfasst von Yugo Yamashita und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Japan (Y. Yamashita, Y. Yoshikawa). Hauptthemen laut MEDLINE: Venous Thromboembolism, Thrombosis, Venous Thrombosis, Neoplasms. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Daiichi-Sankyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis in patients with cancer is clinically relevant, but the evidence is lacking. The prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events; however, it could also increase the risk of bleeding. METHODS: In a multicenter, open-label, adjudicator-blinded, randomized clinical trial at 60 institutions in Japan, we randomly assigned patients with cancer with isolated distal deep vein thrombosis, in a 1-to-1 ratio, to receive either a 12-month or 3-month edoxaban treatment. The primary end point was a composite of a symptomatic recurrent venous thromboembolism (VTE) or VTE-related death at 12 months. The major secondary end point was major bleeding at 12 months, according to the criteria of the International Society on Thrombosis and Haemostasis. The primary hypothesis was that a 12-month edoxaban treatment was superior to a 3-month edoxaban treatment with respect to the primary end point. RESULTS: From April 2019 through June 2022, 604 patients were randomized, and after excluding 3 patients who withdrew consent, 601 patients were included in the intention-to-treat population: 296 patients in the 12-month edoxaban group and 305 patients in the 3-month edoxaban group. The mean age was 70.8 years, 28% of the patients were men, and 20% of the patients had symptoms of deep vein thrombosis at baseline. The primary end point of a symptomatic recurrent VTE event or VTE-related death occurred in 3 of the 296 patients (1.0%) in the 12-month edoxaban group and in 22 of the 305 patients (7.2%) in the 3-month edoxaban group (odds ratio, 0.13; 95% CI, 0.03–0.44). The major secondary end point of major bleeding occurred in 28 of the 296 patients (9.5%) in the 12-month edoxaban group and in 22 of the 305 patients (7.2%) in the 3-month edoxaban group (odds ratio, 1.34; 95% CI, 0.75–2.41). The prespecified subgroups did not affect the estimates on the primary end point. CONCLUSIONS: In patients with cancer with isolated distal deep vein thrombosis, 12 months was superior to 3 months for an edoxaban treatment with respect to the composite outcome of a symptomatic recurrent VTE or VTE-related death. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03895502.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismThrombosisVenous ThrombosisNeoplasmsMaleHumansAgedFemaleAnticoagulantsHemorrhagePyridinesThiazoles

Stichwörter der Autor:innen

anticoagulantcancerdeep vein thrombosisedoxabanrecurrence

Substanzen

AnticoagulantsedoxabanPyridinesThiazoles

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Japan (Y. Yamashita, Y. Yoshikawa).
  • Department of Clinical Epidemiology, Hyogo Medical University, Nishinomiya, Japan (T.M.).
  • Division of Cardiology, Shizuoka Cancer Center, Japan (N.M., T.O.).
  • Division of Vascular Surgery, Department of Surgery, Tohoku University Hospital, Sendai, Japan (M.U., D.A.).
  • Division of Cardiology, Osaka General Medical Center, Japan (Y.N.).
  • Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Japan (Y.S.).

ORCID-Profile: Yugo Yamashita, Takeshi Morimoto, Michihisa Umetsu, Daijirou Akamatsu, Yuji Nishimoto, Yukihito Sato, Takuma Takada, Kentaro Jujo, Yoshito Ogihara, Kaoru Dohi, Nobutaka Ikeda, Kenta Mori, Daisuke Sueta, Yukari Tsubata, Yasuhiro Tanabe, Ryuki Chatani, Naohiko Nakanishi, Satoshi Ikeda, Makoto Mo, Yusuke Yoshikawa, Takeshi Kimura

Förderung

  • Daiichi-Sankyo

Zitieren

APA

Yamashita, Y., Morimoto, T., Muraoka, N., Oyakawa, T., Umetsu, M., Akamatsu, D., Nishimoto, Y., Sato, Y., Takada, T., Jujo, K., Minami, Y., Ogihara, Y., Dohi, K., Fujita, M., Nishikawa, T., Ikeda, N., Hashimoto, G., Otsui, K., Mori, K., …, & ONCO DVT Study Investigators (2023). Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial. Circulation. https://doi.org/10.1161/circulationaha.123.066360

Vancouver

Yamashita Y, Morimoto T, Muraoka N, Oyakawa T, Umetsu M, Akamatsu D, et al. Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial. Circulation. 2023. doi:10.1161/circulationaha.123.066360

BibTeX
@article{Yamashita2023,
  author = {Yamashita, Yugo and Morimoto, Takeshi and Muraoka, Nao and Oyakawa, Takuya and Umetsu, Michihisa and Akamatsu, Daijirou and Nishimoto, Yuji and Sato, Yukihito and Takada, Takuma and Jujo, Kentaro and Minami, Yuichiro and Ogihara, Yoshito and Dohi, Kaoru and Fujita, Masashi and Nishikawa, Tatsuya and Ikeda, Nobutaka and Hashimoto, Go and Otsui, Kazunori and Mori, Kenta and Sueta, Daisuke and Tsubata, Yukari and Shoji, Masaaki and Shikama, Ayumi and Hosoi, Yutaka and Tanabe, Yasuhiro and Chatani, Ryuki and Tsukahara, Kengo and Nakanishi, Naohiko and Kim, Kitae and Ikeda, Satoshi and Mo, Makoto and Yoshikawa, Yusuke and Kimura, Takeshi and ONCO DVT Study Investigators, ONCO DVT Study Investigators},
  title = {Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial},
  journal = {Circulation},
  year = {2023},
  doi = {10.1161/circulationaha.123.066360}
}
Kostenlos starten →